Crescent Biopharma's Capital Efficiency Challenges in the Biopharmaceutical Sector

Font: Financial Modeling Prep  • Mar 05, 2026

• Crescent Biopharma, Inc. (NASDAQ:CBIO) is facing significant challenges in capital efficiency with a Return on Invested Capital (ROIC) of -74.58% and a Weighted Average Cost of Capital (WACC) of 9.98%.
• Pieris Pharmaceuticals (NASDAQ:PIRS) showcases strong capital efficiency with a ROIC of 22.28% against a WACC of 7.52%, making it the most efficient among its peers.
• Other competitors like CytomX Therapeutics (NASDAQ:CTMX), Galmed Pharmaceuticals (NASDAQ:GLMD), Cidara Therapeutics (NASDAQ:CDTX), and MacroGenics (NASDAQ:MGNX) also display varying degrees of capital efficiency challenges, though less severe than CBIO's.

Crescent Biopharma, Inc. (NASDAQ:CBIO) is a company in the biopharmaceutical sector, focusing on developing innovative therapies. The company is currently facing challenges in capital efficiency, as indicated by its financial metrics. In the competitive landscape, CBIO's performance is compared with peers like CytomX Therapeutics, Galmed Pharmaceuticals, Cidara Therapeutics, Pieris Pharmaceuticals, and MacroGenics.

CBIO's Return on Invested Capital (ROIC) is -74.58%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 9.98%. This negative ROIC suggests that CBIO is not generating sufficient returns on its invested capital. The ROIC to WACC ratio of -7.47 further highlights the inefficiency in capital utilization.

In contrast, Pieris Pharmaceuticals (NASDAQ:PIRS) shows a strong ROIC of 22.28% against a WACC of 7.52%, resulting in a ROIC to WACC ratio of 2.96. This indicates that PIRS is effectively generating returns on its invested capital, making it the most efficient among its peers in this analysis.

CytomX Therapeutics (NASDAQ:CTMX) also demonstrates positive capital efficiency with a ROIC of 18.76% and a WACC of 15.09%, leading to a ROIC to WACC ratio of 1.24. This suggests that CTMX is generating returns above its cost of capital, though not as efficiently as PIRS.

Other peers like Galmed Pharmaceuticals (NASDAQ:GLMD), Cidara Therapeutics (NASDAQ:CDTX), and MacroGenics (NASDAQ:MGNX) show negative ROICs, indicating challenges in capital efficiency similar to CBIO. However, their ROIC to WACC ratios are less negative than CBIO's, suggesting relatively better, albeit still inefficient, capital utilization.